{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:00:48Z","timestamp":1768514448199,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jpeds.2022.05.008","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T12:10:08Z","timestamp":1652271008000},"page":"100-107.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy"],"prefix":"10.1016","volume":"248","author":[{"given":"Audrey A.M.","family":"Vollebregt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Ruijter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannerieke","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmee","family":"Oussoren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2022.05.008_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2022.05.008_bib2","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2022.05.008_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2020.07.005","article-title":"Enzyme replacement therapy for the treatment of Hunter disease: a systematic review with narrative synthesis and meta-analysis","volume":"131","author":"Wikman-Jorgensen","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2022.05.008_bib8","first-page":"65","article-title":"Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.jpeds.2022.05.008_bib9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpeds.2022.05.008_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2022.05.008_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A Phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2022.05.008_bib12","doi-asserted-by":"crossref","first-page":"e20211057","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib13","first-page":"73","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"8","author":"Muenzer","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","article-title":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","volume":"21","author":"Seo","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jpeds.2022.05.008_bib15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmg.2010.07.013","article-title":"First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS)","volume":"53","author":"Alcalde-Martin","year":"2010","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jpeds.2022.05.008_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2022.05.008_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jpeds.2022.05.008_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/mgme.1999.2894","article-title":"Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models","volume":"68","author":"Brooks","year":"1999","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib24","first-page":"20","article-title":"Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II","volume":"2","author":"Kim","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.jpeds.2022.05.008_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/clinchem\/38.6.803","article-title":"Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue","volume":"38","author":"de Jong","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.jpeds.2022.05.008_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2022.05.008_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymgme.2014.08.009","article-title":"Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome","volume":"114","author":"Sohn","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2022.05.008_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2022.05.008_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.jpeds.2022.05.008_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2022.05.008_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jpeds.2022.05.008_bib33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10528-012-9538-9","article-title":"Decreasing activity and altered protein processing of human iduronate-2-sulfatase mutations demonstrated by expression in COS7 cells","volume":"50","author":"Charoenwattanasatien","year":"2012","journal-title":"Biochem Genet"},{"key":"10.1016\/j.jpeds.2022.05.008_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis","volume":"29","author":"Sukegawa-Hayasaka","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jpeds.2022.05.008_bib35","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1007\/s10545-008-0876-z","article-title":"Molecular analysis of the iduronate-2-sulfatase gene in Thai patients with Hunter syndrome","volume":"31","author":"Keeratichamroen","year":"2008","journal-title":"J Inherit Metab Dis"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622004140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622004140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:12:33Z","timestamp":1758359553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347622004140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"alternative-id":["S0022347622004140"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.05.008","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}